Logo
x

Search

Subscribe Now

GSK

GSK Reports the US FDA’s NDA Acceptance of Gepotidacin with Priority Review to Treat Uncomplicated Urinary Tract Infections

GSK Reports the US FDA’s NDA Acceptance of Gepotidacin with Priority Review to Treat Uncomplicated Urinary Tract Infections

  • October 16, 2024
GSK Reports the CHMP’s Positive Opinion of Menveo Vaccine Against Invasive Meningococcal Disease

GSK Reports the CHMP’s Positive Opinion of Menveo Vaccine Against Invasive Meningococcal Disease

  • September 24, 2024
GSK Reports Topline Results from the P-III Trial of Arexvy Co-Administered with Shingrix

GSK Reports Topline Results from the P-III Trial of Arexvy Co-Administered with Shingrix

  • September 19, 2024
GSK Reports the NDA Acceptance of Blenrep Combinations by the Japanese MHLW for R/R Multiple Myeloma

GSK Reports the NDA Acceptance of Blenrep Combinations by the Japanese MHLW for R/R Multiple Myeloma

  • September 20, 2024
GSK’s Blenrep Combination Gains the NMPA’s Breakthrough Therapy Designation to Treat R/R Multiple Myeloma

GSK’s Blenrep Combination Gains the NMPA’s Breakthrough Therapy Designation to Treat R/R Multiple Myeloma

  • September 13, 2024
GSK Reports Headline Data from P-II Study of Seasonal Influenza mRNA Vaccine

GSK Reports Headline Data from P-II Study of Seasonal Influenza mRNA Vaccine

  • September 12, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.